No Data
No Data
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Institutional Owners May Be Pleased With Recent Gains After 30% Loss Over the Past Year
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Express News | Watching Monte Rosa Therapeutics, Zura Bio; Shares See Volume Amid TipRanks Issues Report Mentioning The Two Stocks
Monte Rosa Therapeutics Price Target Maintained With a $16.00/Share by Piper Sandler
Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
No Data